Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $356,034.

  • China Pharma Holdings' Depreciation & Amortization (CF) fell 48.91% to $356,034 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 49.25%. This contributed to the annual value of $2.6 million for FY2024, which is 4.92% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Depreciation & Amortization (CF) is $356,034, which was up 10.96% from $320,863 recorded in Q2 2025.
  • China Pharma Holdings' Depreciation & Amortization (CF)'s 5-year high stood at $976,457 during Q3 2021, with a 5-year trough of $320,863 in Q2 2025.
  • For the 3-year period, China Pharma Holdings' Depreciation & Amortization (CF) averaged around $579,812, with its median value being $683,094 (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 45.03% in 2021, then tumbled by 56.60% in 2025.
  • China Pharma Holdings' Depreciation & Amortization (CF) (Quarterly) stood at $710,716 in 2021, then dropped by 10.03% to $639,425 in 2022, then grew by 8.82% to $695,835 in 2023, then tumbled by 35.61% to $448,073 in 2024, then slumped by 48.91% to $356,034 in 2025.
  • Its Depreciation & Amortization (CF) was $356,034 in Q3 2025, compared to $320,863 in Q2 2025 and $329,313 in Q1 2025.